Slide 1: ACTengine IMA203 TCR-T Monotherapy Targeting PRAME – Interim Data Update
Delivering the Power of T cells to Cancer Patients © Immatics. Not for further reproduction or distribution. ACTengine® IMA203 TCR - T Monotherapy Targeting PRAME – Phase 1b Cohort A Interim Data Update Martin Wermke , Professor at the University Hospital Dresden and Coordinating Investigator of the
Slide 2: Forward-Looking Statement
Forward - Looking Statement This presentation (“Presentation”) is provided by Immatics N . V . (“Immatics” or the “Company”) for informational purposes only . The information contained herein does not purport to be all - inclusive and none of Immatics, any of its affiliates, any of its or their resp
Slide 3: Update on IMA203 TCR-T Monotherapy – Delivering a Meaningful Benefit to Patients
Update on IMA203 TCR - T Monotherapy – Phase 1b Cohort A Delivering a Meaningful Benefit to Patients with an Unmet Need 3 Martin Wermke, MD Professor at the University Hospital Dresden, Coordinating Investigator of the ACTengine® IMA203 TCR - T trial Cedrik M. Britten, MD Chief Medical Officer Immat
Slide 4: The Multi-Cancer Opportunity of PRAME
The Multi - Cancer Opportunity of PRAME One of the Most Promising Solid Tumor Targets for TCR - based Therapies Known To Date 4 High prevalence High target density Homogeneous expression “Clean” expression profile Clinical proof - of - concept s q N S C L C Ovarian Cancer PRAME fulfills all properti
Slide 5: Key Pillars of Developing a Successful TCR-T Product Candidate
Unlocking Novel Treatments for Patients with Solid Cancers Key Pillars of Developing a Successful TCR - T Product Candidate 5 S a f e ty Anti - Tumor Activity Durability Product Quality Broad Reach
Slide 6: Summary of Today's Update
Key Pillars of Developing a Successful TCR - T Product Candidate Summary of Today’s Update on IMA203 TCR - T Phase 1b Cohort A S a f e ty Anti - Tumor Activity Durability Product Quality Broad Reach Manageable tolerability at doses as high as ~9x10 9 TCR - T cells High rate of objective responses: 6
Slide 7: ACTengine Phase 1b Design – Focus on Monotherapy in Cohort A
ACTengine® IMA203 TCR - T Phase 1 Design Focus on IMA203 TCR - T Monotherapy Investigated in Cohort A 7 Cohort C Phase 1b Cohort A Interim Update on 11 patients 1 Updated target dose (provisional recommended Phase 2 dose, RP2D) determined at DL4+DL5 for Cohort A and B, for Cohort C treatment of n=3
Slide 8: ACTengine Monotherapy – Patient Flow
ACTengine® IMA203 TCR - T Monotherapy – Patient Flow 8 HLA - A*02 Testing Blood sample; Central lab Treatment & Observation Phase Long Term Follow - up Screening & Manufacturing Phase Manufacturing by Immatics Infusion of ACTengine® IMA203 TCR - T Product Lymphodepletion * Target Profiling Fresh Tum
Slide 9: ACTengine Monotherapy – Patient and Product Characteristics
N =11 ACTengine® IMA203 TCR - T Monotherapy – Phase 1b Cohort A Patient and Product Characteristics D ata c u t - o f f A p r 04 , 202 3 9 Heavily pre - treated, metastatic last - line patients that have exhausted all available standard of care treatments 1 Including ovarian cancer patient A - DL5 -
Slide 10: Most Frequent Adverse Events – Manageable Tolerability
Most Frequent Adverse Events – Phase 1b Cohort A (N=11) Manageable Treatment - emergent Adverse Events (TEAEs) CRS and ICANS graded by CARTOX criteria (Neelapu et al ., 2018); 1 ICANS: Immune Effector Cell - Associated Neurotoxicity Syndrome • Expected cytopenia (Grade 1 - 4) associated with lymphod
Slide 11: Best Overall Response – Deep Objective Responses Independent of Tumor Type
Best Overall Response – Phase 1b Cohort A Deep Objective Responses Independent of Tumor Type 1 Ovarian cancer patient A - DL5 - 04 erroneously received one dose of nivolumab and is part of intent - to - treat population (shown here) but not per - protocol population; 2 Initial ORR: Objective respons
Slide 12: Response over Time – Durable Partial Responses 9+ Months
Response over Time – Phase 1b Cohort A Durable Partial Responses 9+ Months after IMA203 TCR - T Treatment **Ovarian cancer patient A - DL 5 - 04 erroneously received one dose of nivolumab and is part of intent - to - treat population (shown here) but not per - protocol population ; 1 Duration of res
Slide 13: Deep & Durable Responses in Heavily Pre-Treated Patients
Deep & Durable Responses in Heavily Pre - Treated Patients – Phase 1b Cohort A Patient ID Indication No of prior treatment lines Prior treatments Total infused dose TCR - T cells 1 [x10 9 ] BOR BOR (Max % change of target lesions) Comment A - DL5 - 01 Uveal Melanoma 1 ARRY614/Nivolumab 4.16 cPR - 60
Slide 14: Biological Data Consistent with Clinical Data
Biological Data Consistent with Clinical Data IMA203 TCR - T Levels and Tumor Infiltration across Patients in Phase 1a and Phase 1b Cohort A IMA203 T cells found in all evaluable tumor tissues, level of infiltration associated with objective responses 1 Increased levels of IMA203 T cells in the bloo
Slide 15: Responses above Immatics' PRAME RNA Threshold Independent of Tumor Type
Responses above Immatics’ PRAME RNA Threshold Independent of Tumor Type Highlighting Tumor Types (left) and Type of Best Overall Response (right) – Phase 1b Cohort A PRAME RNA expression in pre - treatment biopsies relative to threshold IMA203 achieved objective responses at all expression levels ab
Slide 16: Potential of IMA203 in Additional Solid Cancer Indications
Potential of IMA203 in Additional Solid Cancer Indications Based on PRAME Expression in IMA203 TCR - T Responders – Phase 1b Cohort A Immatics’ proprietary mass spectrometry - guided mRNA threshold 100% 100% 95% 100% 50% (90% 2 ) 80% 60% 65% 25% % PRAME - positive patients 1 PRAME target expression
Slide 17: Summary of Interim Data Update
ACTengine® IMA203 TCR - T Monotherapy Targeting PRAME Summary of Phase 1b Cohort A Interim Data Update • Manageable tolerability with no high - grade CRS, no ICANS in 11 patients in Cohort A 1 • Objective responses observed in heavily pre - treated last - line solid cancer patients including checkpo
Slide 18: Immatics' ACTengine Development Strategy
Immatics’ ACTengine® IMA203 TCR - T Development Strategy Two Pillared Strategy 18 Objective: Deliver best - in - class therapy in 1 - 2 last - line solid cancer types as fast as possible • Focus on indications with PRAME prevalence above 80% with available clinical PoC, such as cut. melanoma (potent
Slide 19: Realizing the Full Multi-Cancer Opportunity of PRAME
Realizing the Full Multi - Cancer Opportunity of PRAME ACTengine® IMA203 (TCR - T) and TCER® IMA402 (TCR Bispecific) 19 Indication % PRAME positive patients 1 Uterine Carcinoma Uterine Carcinosarcoma Sarcoma Subtypes Cut. Melanoma Uveal Melanoma 2 Ovarian Carcinoma Squamous NSCLC T N BC Small Cell L
Slide 20: We are Immensely Grateful to the Patients, Their Families and Investigators
University Hospital Dresden University Hospital Bonn University Hospital Würzburg Columbia University University of Pittsburgh MD Anderson Cancer Center University Hospital Hamburg Dr. D. Araujo Dr. A. Tsimberidou Dr. A. Jazaeri Dr. W. Alsdorf Dr. T. Holderried Dr. M. Chatterjee Dr. J. Luke Ge rma n
Slide 21: Appendix
Delivering the Power of T cells to Cancer Patients © Immatics. Not for further reproduction or distribution. ww w .i mm a ti c s . c o m Appendix
Slide 22: ACTengine 1st Gen Monotherapy Tolerability Data
ACTengine® IMA203 TCR - T 1 st Gen Monotherapy Tolerability Data • IMA203 was well tolerated • No Adverse Event ≥Grade 3 was observed with a frequency ≥10% when excluding expected cytopenias associated with lymphodepletion • No IMA203 - related Grade 5 Adverse Events All treatment - emergent adverse
Slide 23: Focus on IMA203 – All ≥Grade 3 Adverse Events
ACTengine® IMA203 TCR - T 1 st Gen Monotherapy Tolerability Data Focus on IMA203 Phase 1b Cohort A – All ≥Grade 3 Adverse Events (N=11) • IMA203 was well tolerated • No Adverse Event ≥Grade 3 was observed with a frequency ≥10% when excluding expected cytopenias associated with lymphodepletion • No I
Slide 24: Favorable TCR-T Product Characteristics and High TCR-T Levels in Patients
0 2 î 10 5 4 î 10 5 6 î 10 5 8 î 10 5 0. 0025 Favorable TCR - T Product Characteristics and High TCR - T Levels in Patients Manufacturing Improvements Implemented in Phase 1b Enhance Key Features of the Cell Product Manufacturing success rate of 94% to reach provisional RP2D ** Mean cell dose infuse
Slide 25: Focus on Melanoma Patients – Phase 1a and Patient Characteristics
Focus on Melanoma Patients Phase 1a (DL4 only) and Phase 1b Cohort A Patient Characteristics (n=10) Prior lines of treatment Mean (min, max) 4.5 (1, 7) Previous lines of CPI Mean (Min, Max) 2.6 (1, 4) LDH at baseline >1 x ULN [% of patients] 60.0 Baseline tumor burden Mean target lesion sum of diame
Slide 26: Delivering the Power of T cells to Cancer Patients
Delivering the Power of T cells to Cancer Patients © Immatics. Not for further reproduction or distribution. ww w .i mm a ti c s . c o m